Serum neurofilament light chain in behavioral variant frontotemporal dementia
Standard
Serum neurofilament light chain in behavioral variant frontotemporal dementia. / Steinacker, Petra; Anderl-Straub, Sarah; Diehl-Schmid, Janine; Semler, Elisa; Uttner, Ingo; von Arnim, Christine A F; Barthel, Henryk; Danek, Adrian; Fassbender, Klaus; Fliessbach, Klaus; Foerstl, Hans; Grimmer, Timo; Huppertz, Hans-Jürgen; Jahn, Holger; Kassubek, Jan; Kornhuber, Johannes; Landwehrmeyer, Bernhard; Lauer, Martin; Maler, Juan Manuel; Mayer, Benjamin; Oeckl, Patrick; Prudlo, Johannes; Schneider, Anja; Volk, Alexander E; Wiltfang, Jens; Schroeter, Matthias L; Ludolph, Albert C; Otto, Markus; FTLDc Study Group.
In: NEUROLOGY, Vol. 91, No. 15, 09.10.2018, p. E1390-E1401.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Serum neurofilament light chain in behavioral variant frontotemporal dementia
AU - Steinacker, Petra
AU - Anderl-Straub, Sarah
AU - Diehl-Schmid, Janine
AU - Semler, Elisa
AU - Uttner, Ingo
AU - von Arnim, Christine A F
AU - Barthel, Henryk
AU - Danek, Adrian
AU - Fassbender, Klaus
AU - Fliessbach, Klaus
AU - Foerstl, Hans
AU - Grimmer, Timo
AU - Huppertz, Hans-Jürgen
AU - Jahn, Holger
AU - Kassubek, Jan
AU - Kornhuber, Johannes
AU - Landwehrmeyer, Bernhard
AU - Lauer, Martin
AU - Maler, Juan Manuel
AU - Mayer, Benjamin
AU - Oeckl, Patrick
AU - Prudlo, Johannes
AU - Schneider, Anja
AU - Volk, Alexander E
AU - Wiltfang, Jens
AU - Schroeter, Matthias L
AU - Ludolph, Albert C
AU - Otto, Markus
AU - FTLDc Study Group
N1 - © 2018 American Academy of Neurology.
PY - 2018/10/9
Y1 - 2018/10/9
N2 - OBJECTIVE: To determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD).METHODS: Blood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed for the diagnostic potential in relation to functional assessment (Clinical Dementia Rating Scale Sum of Boxes [CDR-SOB], frontotemporal lobar degeneration-related CDR-SOB, Mini-Mental State Examination [MMSE]) and brain volumetry.RESULTS: At baseline, serum NfL level correlated with CSF NfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666, p = 0.0003). Highest serum levels were observed in bvFTD (p <0 0.0001 vs Con and MCI, p = 0.0078 vs AD, respectively). Discrimination of bvFTD from Con/MCI/AD was possible with 91%/74%/74% sensitivity and 79%/74%/58% specificity. At follow-up, serum NfL increased in bvFTD and AD (p = 0.0039 and p = 0.0006, respectively). At baseline and follow-up, NfL correlated with functional scores of patients with bvFTD (e.g., CDR-SOB [baseline] r = 0.4157, p = 0.0006; [follow-up] r = 0.5629, p < 0.0001) and with atrophy in the gray and white matter of many brain regions including frontal and subcortical areas (e.g., frontal lobe: r = -0.5857, p < 0.0001; 95% confidence interval -0.7415 to -0.3701). For patients with AD/MCI, NfL correlated with the functional performance as well (e.g., CDR-SOB [baseline] r = 0.6624, p < 0.0001; [follow-up] r = 0.5659, p = 0.0003) but not with regional brain volumes.CONCLUSIONS: As serum NfL correlates with functional impairment and brain atrophy in bvFTD at different disease stages, we propose it as marker of disease severity, paving the way for its future use as outcome measure for clinical trials.CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with cognitive problems, serum NfL concentration discriminates bvFTD from other forms of dementia.
AB - OBJECTIVE: To determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD).METHODS: Blood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed for the diagnostic potential in relation to functional assessment (Clinical Dementia Rating Scale Sum of Boxes [CDR-SOB], frontotemporal lobar degeneration-related CDR-SOB, Mini-Mental State Examination [MMSE]) and brain volumetry.RESULTS: At baseline, serum NfL level correlated with CSF NfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666, p = 0.0003). Highest serum levels were observed in bvFTD (p <0 0.0001 vs Con and MCI, p = 0.0078 vs AD, respectively). Discrimination of bvFTD from Con/MCI/AD was possible with 91%/74%/74% sensitivity and 79%/74%/58% specificity. At follow-up, serum NfL increased in bvFTD and AD (p = 0.0039 and p = 0.0006, respectively). At baseline and follow-up, NfL correlated with functional scores of patients with bvFTD (e.g., CDR-SOB [baseline] r = 0.4157, p = 0.0006; [follow-up] r = 0.5629, p < 0.0001) and with atrophy in the gray and white matter of many brain regions including frontal and subcortical areas (e.g., frontal lobe: r = -0.5857, p < 0.0001; 95% confidence interval -0.7415 to -0.3701). For patients with AD/MCI, NfL correlated with the functional performance as well (e.g., CDR-SOB [baseline] r = 0.6624, p < 0.0001; [follow-up] r = 0.5659, p = 0.0003) but not with regional brain volumes.CONCLUSIONS: As serum NfL correlates with functional impairment and brain atrophy in bvFTD at different disease stages, we propose it as marker of disease severity, paving the way for its future use as outcome measure for clinical trials.CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with cognitive problems, serum NfL concentration discriminates bvFTD from other forms of dementia.
KW - Journal Article
U2 - 10.1212/WNL.0000000000006318
DO - 10.1212/WNL.0000000000006318
M3 - SCORING: Journal article
C2 - 30209235
VL - 91
SP - E1390-E1401
JO - NEUROLOGY
JF - NEUROLOGY
SN - 0028-3878
IS - 15
ER -
